Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. The FDA Adds a New Condition for Treatment. However, there is one notable example—Epidiolex. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients were granted access to low-THC marijuana oil. Andrew Turnage, the executive director of the Georgia Access to Medical Cannabis Commission, spoke on this fact.

Oil 98

Oil Patients Access THC 98

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. Patients, and their treatment, therefore, are the priority. Treatment options may be limited by government-approved imports, a practitioner’s prescription or pharmacy stock. Legal access does not necessarily equate to financial access.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. Mental health treatment is big business, with the global antidepressant drug market valued at over $13 billion in 2016. Threat to Patient Access in Oregon. The Race to Patent Psilocybin.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. CONVENTIONAL TREATMENT. One of the goals of treating epilepsy is to allow people to continue to live functional and fulfilling life’s epilepsy treatment. CANNABIS AS A POTENTIAL TREATMENT.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Fresh Toast

DECEMBER 21, 2021

As cannabis becomes less stigmatized, the autism community is exploring treatments that are more accessible and less pharmaceutical. THC More Effective Than CBD In Treating Autism, New Preliminary Study Shows.

THC 105

THC CBD Pharmaceutical Treatment 105

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

SEPTEMBER 23, 2021

Note: Veriheal does not support illegally consuming therapeutic substances such as Iboga but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 22, 2022

The Federal Parliament legalised the use of medicinal cannabis products in Australia in February 2016, but access to treatment is still severely limited due to cost, with patients reporting average monthly costs in excess of $300 , or approximately $10 per day. He writes on his website. List Medicinal Cannabis on the PBS.

Pharmaceutical 52

Pharmaceutical Media Medicine Treatment 52

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”

Treatment 98

Treatment Patients Access Research and Development 98

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

NORML

MAY 26, 2020

Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” Chronic pain is the most commonly reported qualifying condition among medical cannabis patients enrolled in state-specific access programs.

Clinical Trials 251

Clinical Trials Chronic Pain Cannabinoids Patients 251

Cannabis Law Report

MAY 2, 2023

Australian cannabis company Cannatrek has launched a not-for-profit organisation dedicated to providing support and access to medicinal cannabis therapies for vulnerable groups. Medicinal cannabis is still quite expensive, […]

Therapy 52

Therapy Pharmaceutical Medicine Treatment 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Fresh Toast

AUGUST 19, 2019

With the stigma of cannabis fading by the day, more families are exploring treatments that are more accessible and less pharmaceutical. Continue reading The Potential Of CBD And Cannabis Within The Anxiety And Autism Community at The Fresh Toast.

CBD 111

CBD Pharmaceutical Treatment Access 111

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. However, challenges remain in ensuring equitable access to participation in the legal cannabis market and addressing disparities in ownership and representation.

Legalization 52

Legalization Access Programs Education 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

MGC Pharma

FEBRUARY 22, 2018

While at home in Australia, the Medical Cannabis industry is still working hard to gather more evidence-based research to substantiate treatment assertions, relevant studies are already occurring overseas. It’s heartening to see the release of more and more evidence-based global research surrounding Medical Cannabis-based treatment.

Research and Development 100

Research and Development Pharmaceutical Chronic Pain Treatment 100

MMJ Recs

FEBRUARY 3, 2024

Pennsylvania Medical Cannabis Program and Philadelphia Marijuana Dispensaries The Pennsylvania Medical Cannabis Program serves as the foundation for medical marijuana accessibility in Philadelphia. In Philadelphia, patients must be diagnosed with specific medical conditions to be eligible for medical cannabis treatment.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “This year, my focus was on program improvements to further expand both access and therapeutic value to benefit the health and well-being of all Virginians.”

Law 259

Law Patients Access Oil 259

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

JULY 21, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir Nath as Chief Executive Officer, effective August 1, 2022. London, UK July 19, 2022.

Therapy 52

Therapy Research and Development Pharmaceutical Patients 52

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

TheAnswerPage

MAY 18, 2022

Epidiolex is an FDA-approved oral CBD solution indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in one year of age and older. GW Pharmaceuticals press release: “GW Pharmaceuticals plc and Its U.S. link] Accessed April 30, 2020.

Pharmaceutical 52

Pharmaceutical Treatment Access CBD 52

TheAnswerPage

JUNE 12, 2021

Epidiolex is an FDA-approved oral CBD solution indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in one year of age and older. GW Pharmaceuticals press release: “GW Pharmaceuticals plc and Its U.S. link] Accessed April 30, 2020.

Pharmaceutical 52

Pharmaceutical Access Treatment CBD 52

Cannabis Law Report

MARCH 29, 2022

Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior to his work at Moderna, Mullette developed broad pharmaceutical expertise with Sanofi in a variety of management roles in the U.S., Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. He holds a B.S.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

SEPTEMBER 14, 2022

The cannabis-based treatment, Sativex, will now be available via NHS prescription in Scotland, to treat spasticity in MS patients. Although a limited number of people have been able to access it via the Peer Approved Clinical System (PACS) Tier 2 individual patient treatment request process.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

NOVEMBER 17, 2021

There is one problem, Malaysia currently has no registered cannabis-based treatment. The National Pharmaceutical Regulatory agency (NPRA) approved Sativex in 2014 for patients experiencing muscle spasms and spasticity from multiple sclerosis. Importers would be required to hold permits and licenses. Sativex in Malaysia.

Research and Development 111

Research and Development Patients Treatment Pharmaceutical 111

MGC Pharma

FEBRUARY 21, 2018

Armed with a well-developed agricultural sector, high environmental standards, world class pharmaceutical manufacturing standards, a like-minded government, and grassroot support for the industry, there can be no doubt that Australia is poised to become a Medical Cannabis powerhouse. It’s a climactic time for the Medical Cannabis industry.

Research and Development 100

Research and Development Pharmaceutical Patients Medicine 100